Payment overview · 2025
General Payments
$1,109.24
43 reported records · 18 companies
Healthcare provider profile · identity verified
Marina E Manvelyan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, CA · NPI 1215925409
Verified facts
What the public records show
CMS Open Payments records show Marina E Manvelyan, MD received $1,109.24 in general payments during 2025 across 43 reported records.
Abbott Laboratories accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $196.26 | 17.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.53 | 12.9% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $89.22 | 8.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.53 | 7.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $81.05 | 7.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66.79 | 6.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.63 | 5.7% | 3 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $51.89 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.73 | 4.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $46.57 | 4.2% | 2 | 2025 |
| Ultragenyx Pharmaceutical Inc. | Unresolved — no canonical attribution shown | $45.08 | 4.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.15 | 3.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.38 | 3.6% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.00 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.31 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.22 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.61 | 1.3% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $14.29 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,109.24 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $196.26 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $173.75 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $123.60 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $81.05 | 4 | 2025 |
Source payment records
|
|||||
| N/A Normalized: n a |
Device | DePuy Synthes Sales Inc. | $51.89 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $48.28 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| Dojolvi Normalized: dojolvi |
Drug | Ultragenyx Pharmaceutical Inc. | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.77 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.63 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.31 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 77 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 244 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
190 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 810 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 668 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 637 | 137 |
| Gabapentin | Gabapentin | 616 | 112 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 567 | 111 |
| Metformin Hcl | Metformin Hcl | 458 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 101 |
| Losartan Potassium | Losartan Potassium | 396 | 86 |
| Carvedilol | Carvedilol | 372 | 65 |
| Furosemide | Furosemide | 362 | 79 |
| Escitalopram Oxalate | Escitalopram Oxalate | 280 | 60 |
| Omeprazole | Omeprazole | 269 | 60 |
| Potassium Chloride | Potassium Chloride | 246 | 48 |
| Eliquis | Apixaban | 244 | 37 |
| Famotidine | Famotidine | 227 | 50 |
| Vascepa | Icosapent Ethyl | 202 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 197 | 40 |
| Farxiga | Dapagliflozin Propanediol | 190 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 42 |
| Dexlansoprazole Dr | Dexlansoprazole | 183 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 183 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 47 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 176 | 61 |
| Lisinopril | Lisinopril | 175 | 42 |
| Tramadol Hcl | Tramadol Hcl | 174 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 169 | 24 |
| Lorazepam | Lorazepam | 168 | 41 |
| Jardiance | Empagliflozin | 157 | 23 |
| Tradjenta | Linagliptin | 157 | 27 |
| Simvastatin | Simvastatin | 154 | 28 |
| Sertraline Hcl | Sertraline Hcl | 140 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 136 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 37 |
| Azithromycin | Azithromycin | 130 | 99 |
| Allopurinol | Allopurinol | 129 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 27 |
| Meclizine Hcl | Meclizine Hcl | 126 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 22 |
| Atenolol | Atenolol | 118 | 19 |
| Januvia | Sitagliptin Phosphate | 114 | 17 |
| Clonidine Hcl | Clonidine Hcl | 112 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 21 |
| Ozempic | Semaglutide | 108 | 15 |
| Ibuprofen | Ibuprofen | 105 | 18 |
| Montelukast Sodium | Montelukast Sodium | 103 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 25 |
| Alprazolam | Alprazolam | 95 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 94 | 74 |
| Amiodarone Hcl | Amiodarone Hcl | 93 | 17 |
| Lidocaine | Lidocaine | 90 | 17 |
| Metformin Hcl Er | Metformin Hcl | 90 | 23 |
| Xarelto | Rivaroxaban | 88 | 20 |
| Cyclosporine | Cyclosporine | 86 | 13 |
| Alendronate Sodium | Alendronate Sodium | 85 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 32 |
| Pitavastatin Calcium | Pitavastatin Calcium | 83 | 26 |
| Trazodone Hcl | Trazodone Hcl | 81 | 19 |
| Creon | Lipase/Protease/Amylase | 77 | 14 |
| Prednisone | Prednisone | 77 | 45 |
| Ezetimibe | Ezetimibe | 73 | 15 |
| Celecoxib | Celecoxib | 72 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 11 |
| Repatha Sureclick | Evolocumab | 72 | 11 |
| Glipizide | Glipizide | 71 | suppressed |
| Colchicine | Colchicine | 69 | 12 |
| Donepezil Hcl | Donepezil Hcl | 68 | 17 |
| Benazepril Hcl | Benazepril Hcl | 67 | 15 |
| Glimepiride | Glimepiride | 67 | 12 |
| Linzess | Linaclotide | 67 | suppressed |
| Cephalexin | Cephalexin | 66 | 50 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 15 |
| Mirtazapine | Mirtazapine | 64 | 17 |
| Trulicity | Dulaglutide | 64 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 24 |
| Baclofen | Baclofen | 62 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 15 |
| Memantine Hcl | Memantine Hcl | 62 | 12 |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Ketoconazole | Ketoconazole | 60 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 60 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 51 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 58 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 57 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 15 |
| Levofloxacin | Levofloxacin | 55 | 45 |
| Meloxicam | Meloxicam | 55 | 14 |
| Amoxicillin | Amoxicillin | 54 | 50 |
| Lansoprazole | Lansoprazole | 54 | suppressed |
| Mounjaro | Tirzepatide | 53 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 50 | 17 |
| Glipizide Er | Glipizide | 49 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Clotrimazole | Clotrimazole | 47 | 12 |
| Irbesartan | Irbesartan | 47 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 46 | suppressed |
| Methocarbamol | Methocarbamol | 46 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 12 |
| Spironolactone | Spironolactone | 45 | 11 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Valsartan | Valsartan | 45 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 44 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Ranolazine Er | Ranolazine | 43 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 42 | suppressed |
| Myrbetriq | Mirabegron | 41 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Telmisartan | Telmisartan | 40 | suppressed |
| Finasteride | Finasteride | 39 | 13 |
| Methylprednisolone | Methylprednisolone | 39 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 13 |
| Nitroglycerin | Nitroglycerin | 38 | 15 |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 20 |
| Fluocinonide | Fluocinonide | 36 | suppressed |
| Nystatin | Nystatin | 36 | 15 |
| Dapagliflozin | Dapagliflozin Propanediol | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Nexium | Esomeprazole Magnesium | 35 | suppressed |
| Methimazole | Methimazole | 34 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | 11 |
| Estradiol | Estradiol | 31 | 12 |
| Mupirocin | Mupirocin | 31 | 24 |
| Valacyclovir | Valacyclovir Hcl | 31 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Propylthiouracil | Propylthiouracil | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 12 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Procto-Med Hc | Hydrocortisone | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | 12 |
| Naproxen | Naproxen | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 22 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Febuxostat | Febuxostat | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Dexilant | Dexlansoprazole | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 11 |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 15 | suppressed |
| Exemestane | Exemestane | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Crestor | Rosuvastatin Calcium | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Mesalamine Dr | Mesalamine | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,109.24 · 43 records | Abbott Laboratories | ABRYSVO, AREXVY, AUSTEDO XR, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, Dojolvi, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fibroscan, KRYSTEXXA, Kerendia, N/A, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, ZAVZPRET, ZENPEP, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error